Revenue
2009
2010
2011
2012
2013
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
INSMED Inc (INSM)
Price$104.44Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $606.4M | $363.7M | $305.2M | $245.4M | $188.5M | $164.4M | $136.5M | $9.8M | $0 | $0 | $0 | N/A | $11.5M | $0 | $4.4M | $6.9M | $10.4M |
| Gross profit | $483.5M | $278.0M | $239.6M | $190.2M | $144.3M | $124.5M | $112.3M | $7.4M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross margin | 79.73% | 76.43% | 78.52% | 77.53% | 76.57% | 75.75% | 82.26% | 75.36% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Research & development | $771.1M | $598.4M | $571.0M | $397.5M | $272.7M | $181.2M | $131.7M | $145.3M | $109.7M | $122.7M | $74.3M | $56.3M | $44.3M | $29.8M | $28.6M | $4.7M | $9.2M |
| Operating expenses | $1.73B | $1.16B | $949.3M | $647.6M | $519.4M | $389.8M | $347.5M | $314.8M | $188.9M | $173.4M | $117.5M | $87.4M | $66.5M | $42.4M | $66.1M | $15.0M | $19.0M |
| Operating income | −$1.25B | −$878.3M | −$709.6M | −$457.3M | −$375.1M | −$265.2M | −$235.2M | −$307.3M | −$188.9M | −$173.4M | −$117.5M | −$87.4M | −$55.0M | −$42.4M | −$61.7M | −$8.1M | −$8.7M |
| Operating margin | −205.59% | −241.47% | −232.51% | −186.39% | −199.03% | −161.32% | −172.38% | −3,124.94% | N/A | N/A | N/A | N/A | −478.39% | N/A | −1,397.31% | −116.92% | −83.62% |
| EBITDA | −$1.23B | −$867.2M | −$704.1M | −$452.0M | −$366.0M | −$256.1M | −$230.0M | −$303.7M | −$186.0M | −$171.0M | −$115.5M | −$86.3M | −$54.3M | −$41.9M | −$61.4M | −$8.0M | −$8.0M |
| EBITDA margin | −202.88% | −238.44% | −230.70% | −184.23% | −194.20% | −155.79% | −168.57% | −3,088.34% | N/A | N/A | N/A | N/A | −472.48% | N/A | −1,389.54% | −116.14% | −76.81% |
| Net income | −$1.28B | −$913.8M | −$749.6M | −$481.5M | −$434.7M | −$294.1M | −$254.3M | −$324.3M | −$192.6M | −$176.3M | −$118.2M | −$79.2M | −$56.1M | −$41.4M | −$59.7M | −$6.4M | $118.3M |
| Net profit margin | −210.54% | −251.24% | −245.59% | −196.26% | −230.63% | −178.87% | −186.37% | −3,297.17% | N/A | N/A | N/A | N/A | −487.59% | N/A | −1,350.78% | −92.96% | 1,140.94% |
| Basic EPSper basic share | -$6.42 | -$5.57 | -$5.34 | -$3.91 | -$3.88 | -$3.01 | -$3.01 | -$4.22 | -$2.89 | -$2.85 | -$2.02 | -$1.84 | -$1.60 | -$1.56 | -$29.50 | -$4.90 | $93.10 |
| Diluted EPSper diluted share | -$6.42 | -$5.57 | -$5.34 | -$3.91 | -$3.88 | -$3.01 | -$3.01 | -$4.22 | -$2.89 | -$2.85 | -$2.02 | -$1.84 | -$1.60 | -$1.56 | -$29.50 | -$4.90 | $93.00 |
Owners
Reported shareholders
7.40%of listed shares
FMR LLC16.14M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
FMR LLC | 7.40%16.14M shares |
BlackRock, Inc. | 7.24%15.81M shares |
JPMORGAN CHASE & CO | 4.78%10.43M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 4.77%10.41M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.49%9.79M shares |
BAKER BROS. ADVISORS LP | 4.03%8.8M shares |
Capital International Investors | 3.77%8.24M shares |
Darwin Global Management, Ltd. | 2.95%6.43M shares |
AMERIPRISE FINANCIAL INC | 2.83%6.18M shares |
Orbis Allan Gray Ltd | 2.78%6.08M shares |
STATE STREET CORP | 2.77%6.05M shares |
D. E. Shaw & Co., Inc. | 2.69%5.88M shares |
Artisan Partners Limited Partnership | 2.49%5.44M shares |
RTW INVESTMENTS, LP | 2.22%4.84M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.93%4.22M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 1.56%3.41M shares |
NORGES BANK | 1.55%3.38M shares |
Jupiter Topco LLC | 1.19%2.61M shares |
UBS Group AG | 1.18%2.58M shares |
CITADEL ADVISORS LLC | 1.17%2.56M shares |
Percentages use 218.28M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Oct 21, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Sep 9, 2026Form 4 | Brennan David RDirector | SellCommon Stock | 25.0K | $124.00 | $3.10M | 39.2K |
| Aug 17, 2026Form 4 | SHAROKY MELVIN MDDirector | SellCommon Stock · indirect | 5.0K | $127.53 | $637.6K | 0 |
| Aug 10, 2026Form 4 | Adsett RogerChief Operating Officer | SellCommon Stock | 239.8K | $133.27 | $31.96M | 98.7K |
| Aug 6, 2026Form 4 · 10b5-1 | Flammer Martina M.D.Chief Medical Officer | SellCommon Stock | 18.3K | $129.40 | $2.37M | 60.5K |
| Aug 6, 2026Form 4 · 10b5-1 | Flammer Martina M.D.Chief Medical Officer | SellCommon Stock | 8.9K | $127.00 | $1.13M | 78.8K |
Community posts
Insmed raises sales floors as Brinsupri revenue reaches $400 million
Insmed ($INSM) reported third-quarter 2026 revenue of $524.4 million, with Brinsupri contributing $400.1 million, up 29% from the preceding quarter. Arikayce sales increased 9% from a year earlier to $124.4 million, helped by international ...
